# OnCo record nct04410796 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04410796/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04410796", "NCT04410796" ;
  schema:name "Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers"@en ;
  schema:description "A phase 2 trial of osimertinib, carboplatin and pemetrexed in lung cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04410796/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04410796> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest", "lung-deep-dive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/egfr-mutant-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/pemetrexed/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/guardant-health/> .